For Q3/10, TNGN reported an adjusted net loss of $6.7M or $0.54 per basic and diluted common share. Read more…
BMTI has received orphan drug designation from the FDA for its protein therapeutic, recombinant human platelet derived growth factor (rhPDGF-BB), Read more…
Researchers for the first time have induced robust regeneration of nerve tissue connections in injured adult spinal cord sites that control voluntary movement. Read more…
Tissue Regenix received EU CE Marking for its dCELL vascular patch. Read more…
Biomet’s subsidiary, Biomet Biologics, has enrolled the 1st subject into its multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial for critical limb ischemia (CLI). Read more…
Oxeco has conditionally agreed to acquire regenerative therapies firm, Tissue Regenix (TR) for £12 M ($17.53 M) in shares. Oxeco, in addition, reported that it has conditionally raised £4.5 M ($6.57 M) before expenses by way of a placing. It is expected to bolster the newly combined firm’s working capital to about £7.4 M ($10.81 M) net. Read more…
Although congenital heart disease represents the most common major birth defect, scientists have not previously identified the common variation in the genes that give rise to it. Now genetics and cardiology researchers have discovered a genetic variant on chromosome 5 that strongly raises the risk of congenital heart disease. Read more…
Complete corneal wound healing observed in patients with chronic eye ulcers. In the study, 4 patients with chronic neurotrophic keratitis, a degenerative corneal disease induced by nerve impairment, were treated with RGN-259 under a compassionate use IND. Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.